TROP-2–Targeted ADCs for NSCLC: Integrating a New Therapeutic Option

Get up to date on the latest clinical evidence and benefits and nuances of incorporating TROP-2–targeted antibody–drug conjugates into the care of patients with advanced NSCLC by reviewing a CME-certified on-demand webcast and downloadable slides derived from a live symposium, along with a commentary where experts answer frequently asked questions. 

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.